# JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis

> **NCT07530224** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shixiu Wu** · enrollment: 35 (estimated)

## Conditions studied

- Immune Checkpoint Inhibitor-Induced Dermatitis

## Interventions

- **DRUG:** treated with JAK inhibitors orally for 28 days

## Key facts

- **NCT ID:** NCT07530224
- **Lead sponsor:** Shixiu Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07530224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07530224, "JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07530224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*